X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2995) 2995
Newsletter (22) 22
Book Chapter (7) 7
Newspaper Article (7) 7
Dissertation (3) 3
Conference Proceeding (2) 2
Transcript (2) 2
Magazine Article (1) 1
Publication (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2034) 2034
colistin (1705) 1705
anti-bacterial agents - therapeutic use (1112) 1112
colistin - therapeutic use (1096) 1096
microbiology (981) 981
infectious diseases (974) 974
male (896) 896
pharmacology & pharmacy (881) 881
female (825) 825
antibiotics (750) 750
anti-bacterial agents - pharmacology (694) 694
infections (631) 631
microbial sensitivity tests (592) 592
middle aged (583) 583
adult (546) 546
drug resistance (544) 544
colistin - pharmacology (502) 502
bacteria (494) 494
drug resistance, multiple, bacterial (464) 464
aged (455) 455
animals (431) 431
anti-bacterial agents - administration & dosage (425) 425
gram-negative bacteria (414) 414
colistin - administration & dosage (401) 401
pseudomonas-aeruginosa (389) 389
acinetobacter baumannii - drug effects (388) 388
acinetobacter infections - drug therapy (355) 355
antimicrobial agents (336) 336
pneumonia (334) 334
pseudomonas infections - drug therapy (332) 332
treatment outcome (319) 319
acinetobacter baumannii (314) 314
drug resistance in microorganisms (313) 313
pseudomonas aeruginosa (305) 305
epidemiology (301) 301
health aspects (291) 291
ventilator-associated pneumonia (285) 285
mortality (280) 280
pseudomonas aeruginosa - drug effects (279) 279
critically-ill patients (276) 276
infectious disease (265) 265
antibacterial agents (263) 263
tigecycline (256) 256
retrospective studies (251) 251
acinetobacter infections - microbiology (250) 250
nosocomial infections (249) 249
acinetobacter-baumannii (248) 248
drug resistance, bacterial (246) 246
drug therapy, combination (244) 244
research (233) 233
antimicrobial resistance (228) 228
adolescent (227) 227
intravenous colistin (221) 221
therapy (218) 218
polymyxin-b (216) 216
hospitals (215) 215
gram-negative bacterial infections - drug therapy (214) 214
biochemical phenomena, metabolism, and nutrition (211) 211
anti-bacterial agents - adverse effects (209) 209
enterobacteriaceae (209) 209
genes (207) 207
pharmacokinetics (205) 205
risk factors (204) 204
child (199) 199
resistance (197) 197
aged, 80 and over (194) 194
colistin - adverse effects (193) 193
pathogens (193) 193
infection (192) 192
polymyxins (190) 190
klebsiella-pneumoniae (188) 188
e coli (186) 186
analysis (185) 185
acinetobacter baumannii - isolation & purification (180) 180
escherichia-coli (180) 180
klebsiella pneumoniae - drug effects (179) 179
immunology (178) 178
bacterial infections and mycoses (173) 173
drug therapy (169) 169
bacterial pneumonia (168) 168
gram-negative bacteria - drug effects (168) 168
polycyclic compounds (166) 166
cross infection - drug therapy (164) 164
intensive care units (162) 162
antibiotic resistance (160) 160
patients (157) 157
drug synergism (156) 156
emergence (156) 156
polymyxins - therapeutic use (156) 156
multidrug-resistant (153) 153
laboratories (151) 151
multidrug resistance (151) 151
internal medicine (150) 150
medicine (150) 150
care and treatment (149) 149
colistin resistance (149) 149
lipids (149) 149
imipenem (147) 147
anti-bacterial agents - pharmacokinetics (146) 146
carbapenems - pharmacology (146) 146
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2756) 2756
French (78) 78
German (65) 65
Italian (57) 57
Russian (31) 31
Spanish (31) 31
Japanese (21) 21
Portuguese (21) 21
Czech (10) 10
Chinese (6) 6
Dutch (6) 6
Romanian (6) 6
Polish (4) 4
Turkish (3) 3
Swedish (2) 2
Danish (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Antimicrobial agents and chemotherapy, ISSN 0066-4804, 10/2015, Volume 59, Issue 10, pp. 5903 - 5908
New antibiotic options are urgently needed for the treatment of carbapenem-resistant Enterobacteriaceae infections. We report a 64-year-old female with... 
URINARY-TRACT-INFECTIONS | THERAPY | IMIPENEM | EFFICACY | BETA-LACTAMASE | CEFTAZIDIME-AVIBACTAM | BLOOD-STREAM | REGIMEN | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | OUTCOMES | ENTEROBACTERIACEAE | Klebsiella pneumoniae - drug effects | Klebsiella Infections - pathology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Minocycline - analogs & derivatives | Ganciclovir - analogs & derivatives | Colectomy | beta-Lactamases - biosynthesis | Intestine, Small - transplantation | Bacteremia - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Minocycline - therapeutic use | Drug Resistance, Multiple, Bacterial | Ganciclovir - therapeutic use | Azabicyclo Compounds - therapeutic use | Colistin - therapeutic use | Female | Thienamycins - therapeutic use | Klebsiella Infections - drug therapy | Antiviral Agents - therapeutic use | Intestine, Small - microbiology | Bacteremia - drug therapy | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Klebsiella Infections - microbiology | Carbapenems - therapeutic use | Intestine, Small - drug effects | Klebsiella pneumoniae - enzymology | Klebsiella pneumoniae - growth & development | Bacterial Proteins - biosynthesis | Bacteremia - pathology | Ceftazidime - therapeutic use | Challenging Clinical Cases in Antimicrobial Resistance
Journal Article
Expert review of anti-infective therapy, ISSN 1744-8336, 2014, Volume 6, Issue 5, pp. 593 - 600
...; one of the most promising ones is the evaluation and use of old antibiotic compounds... 
aminoglycoside | Acinetobacter baumannii | multiple-drug resistant | fusidic acid | polymyxin B | Pseudomonas aeruginosa | chloramphenicol | fosfomycin | colistin | Colistin | Aminoglycoside | Fusidic acid | Chloramphenicol | Polymyxin B | Fosfomycin | Multiple-drug resistant | VENTILATOR-ASSOCIATED PNEUMONIA | NATURAL-PRODUCTS | RESISTANT STAPHYLOCOCCUS-AUREUS | ANTIBACTERIAL DRUG DISCOVERY | GRAM-NEGATIVE BACTERIA | INTENSIVE-CARE-UNIT | PSEUDOMONAS-AERUGINOSA | PHARMACOLOGY & PHARMACY | CYSTIC-FIBROSIS | CRITICALLY-ILL PATIENTS | TRIMETHOPRIM-SULFAMETHOXAZOLE | Fusidic Acid - administration & dosage | Humans | Drug Resistance, Bacterial | Drug Utilization | Anti-Bacterial Agents - therapeutic use | Aminoglycosides - administration & dosage | Colistin - therapeutic use | Anti-Bacterial Agents - adverse effects | Colistin - adverse effects | Fosfomycin - therapeutic use | Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage | Bacterial Infections - drug therapy | Fosfomycin - adverse effects | Colistin - administration & dosage | Fusidic Acid - adverse effects | Chloramphenicol - therapeutic use | Trimethoprim, Sulfamethoxazole Drug Combination - adverse effects | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Fusidic Acid - therapeutic use | Chloramphenicol - adverse effects | Anti-Bacterial Agents - classification | Fosfomycin - administration & dosage | Aminoglycosides - adverse effects | Anti-Bacterial Agents - administration & dosage | Aminoglycosides - therapeutic use | Chloramphenicol - administration & dosage | Drug resistance in microorganisms | Pseudomonas aeruginosa infections | Usage | Antibiotics | Research | Drug therapy | Health aspects | Risk factors | Index Medicus
Journal Article
International journal of antimicrobial agents, ISSN 0924-8579, 2012, Volume 39, Issue 2, pp. 105 - 114
Journal Article
DEUTSCHES ARZTEBLATT INTERNATIONAL, ISSN 1866-0452, 05/2018, Volume 115, Issue 20-21, pp. 345 - 345
... in therapeutic decision-making, particularly because of the high frequency of co-resistance. Methods: This review is based on pertinent... 
ACINETOBACTER-BAUMANNII | MEDICINE, GENERAL & INTERNAL | URINARY-TRACT-INFECTIONS | ENTEROBACTERIACEAE INFECTIONS | IMIPENEM-CILASTATIN | COMPLICATED INTRAABDOMINAL INFECTIONS | CEFTAZIDIME-AVIBACTAM | DOUBLE-BLIND | BETA-LACTAMASE INHIBITOR | KLEBSIELLA-PNEUMONIAE | SIDEROPHORE CEPHALOSPORIN | Klebsiella pneumoniae - drug effects | Ceftazidime - pharmacology | Escherichia coli - drug effects | Humans | Cephalosporins - standards | Piperacillin - standards | Cephalosporins - therapeutic use | Piperacillin - pharmacology | Carbapenems - pharmacology | Colistin - pharmacology | Pseudomonas aeruginosa - pathogenicity | Escherichia coli - pathogenicity | Fluoroquinolones - standards | Colistin - therapeutic use | Cephalosporins - pharmacology | Tigecycline - therapeutic use | Fosfomycin - therapeutic use | Fosfomycin - pharmacology | Fluoroquinolones - therapeutic use | Pseudomonas aeruginosa - drug effects | Carbapenems - standards | Gram-Negative Bacteria - drug effects | Drug Therapy, Combination - methods | Carbapenems - therapeutic use | Klebsiella pneumoniae - pathogenicity | Fluoroquinolones - pharmacology | Aminoglycosides - pharmacology | Carbapenem-Resistant Enterobacteriaceae - drug effects | Tigecycline - pharmacology | Ceftazidime - therapeutic use | Drug Therapy, Combination - standards | Germany | Aminoglycosides - therapeutic use | Piperacillin - therapeutic use | Review
Journal Article
Expert Review of Anti-infective Therapy, ISSN 1478-7210, 02/2013, Volume 11, Issue 2, pp. 159 - 177
The increasing incidence of carbapenem-resistant Klebsiella pneumoniae (CR-KP) fundamentally alters the management of patients at risk to be colonized or... 
carbapenem-resistant Klebsiella pneumoniae | carbapenemase-producing strains | combination antimicrobial therapy | INFECTIOUS DISEASES | MULTIDRUG-RESISTANT | RISK-FACTORS | VENTILATOR-ASSOCIATED PNEUMONIA | ACUTE-CARE FACILITIES | COMBINATION THERAPY | MICROBIOLOGY | METALLO-BETA-LACTAMASE | COLISTIN METHANESULFONATE | PSEUDOMONAS-AERUGINOSA | MOLECULAR EPIDEMIOLOGY | PHARMACOLOGY & PHARMACY | CRITICALLY-ILL PATIENTS | Klebsiella pneumoniae - drug effects | Minocycline - pharmacology | Carbapenems - administration & dosage | Humans | Minocycline - analogs & derivatives | Anti-Bacterial Agents - therapeutic use | Klebsiella Infections - epidemiology | Carbapenems - pharmacology | Colistin - pharmacology | Aminoglycosides - administration & dosage | Minocycline - therapeutic use | Colistin - therapeutic use | Minocycline - administration & dosage | Rifampin - therapeutic use | Rifampin - administration & dosage | Drug Therapy, Combination | Fosfomycin - therapeutic use | Klebsiella Infections - drug therapy | Fosfomycin - pharmacology | Risk Factors | Colistin - administration & dosage | Carbapenems - therapeutic use | Fosfomycin - administration & dosage | Anti-Bacterial Agents - pharmacology | Rifampin - pharmacology | Aminoglycosides - pharmacology | Anti-Bacterial Agents - administration & dosage | Aminoglycosides - therapeutic use | Klebsiella | Care and treatment | Usage | Antibiotics | Research | Carbapenems | Drug resistance | Health aspects
Journal Article
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1744-7666, 2014, Volume 15, Issue 10, pp. 1351 - 1370
Introduction: In the era of multidrug-resistant, extensively drug-resistant (XDR) and even pandrug-resistant Gram-negative microorganisms, the medical... 
extended spectrum β lactamase | eravacycline | pandrug-resistant | tigecycline | ceftolozane | multidrug-resistant | carbapenem-producing β-lactamases | carbapenem resistance | extensively drug-resistant | avibactam | plazomicin | fosfomycin | colistin | Pandrug-resistant | Colistin | Extended spectrum β lactamase | Plazomicin | Avibactam | Carbapenem resistance | Carbapenem-producing β-lactamases | Extensively drug-resistant | Fosfomycin | Multidrug-resistant | Eravacycline | Ceftolozane | Tigecycline | carbapenem-producing beta-lactamases | URINARY-TRACT-INFECTIONS | VENTILATOR-ASSOCIATED PNEUMONIA | HOSPITAL-ACQUIRED PNEUMONIA | INTENSIVE-CARE UNITS | LACTAMASE INHIBITOR COMBINATION | METALLO-BETA-LACTAMASE | PHARMACOLOGY & PHARMACY | extended spectrum beta lactamase | CRITICALLY-ILL PATIENTS | IN-VITRO ACTIVITY | BLOOD-STREAM INFECTIONS | KLEBSIELLA-PNEUMONIAE | Drugs, Investigational - pharmacology | Klebsiella pneumoniae - drug effects | Humans | Bacteremia - drug therapy | Drugs, Investigational - therapeutic use | Gram-Negative Bacterial Infections - drug therapy | Clinical Trials as Topic | Pseudomonas aeruginosa - drug effects | Bacteremia - microbiology | Gram-Negative Bacterial Infections - microbiology | Anti-Bacterial Agents - therapeutic use | Gram-Negative Bacteria - drug effects | Pneumonia, Ventilator-Associated - microbiology | Drug Resistance, Multiple, Bacterial | Anti-Bacterial Agents - pharmacology | Acinetobacter baumannii - drug effects | Pneumonia, Ventilator-Associated - drug therapy | Index Medicus | Review | Reviews
Journal Article
Drugs, ISSN 0012-6667, 11/2000, Volume 60, Issue 5, pp. 1053 - 1064
Pseudomonas aeruginosa is a non-capsulate and non-sporing Gram-negative bacillus that most commonly affects the lower respiratory system in humans.... 
Meropenem, therapeutic use | Piperacillin, therapeutic use | Azlocillin, therapeutic use | Aztreonam, therapeutic use | Cystic fibrosis | Ticarcillin, therapeutic use | Ceftazidime, therapeutic use | Ciprofloxacin, therapeutic use | Antibacterials, therapeutic use | Tazobactam/piperacillin, therapeutic use | Amikacin, therapeutic use | Peptides, therapeutic use | Gentamicin, therapeutic use | Colistin, therapeutic use | Antimicrobial resistance | Pseudomonal infections, treatment | Imipenem, therapeutic use | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | BURKHOLDERIA-CEPACIA | AERUGINOSA | THERAPY | TOBRAMYCIN | IN-VITRO ACTIVITIES | EXACERBATIONS | BETA-LACTAM ANTIBIOTICS | PHARMACOLOGY & PHARMACY | PIPERACILLIN | TOXICOLOGY | ANTIMICROBIAL PEPTIDES | GENTAMICIN | Lung - microbiology | Lung - pathology | Pseudomonas Infections - etiology | Cystic Fibrosis - microbiology | Pseudomonas Infections - drug therapy | Humans | Respiratory Tract Infections - drug therapy | Hospitalization | Pseudomonas aeruginosa - drug effects | Cystic Fibrosis - complications | Anti-Bacterial Agents - therapeutic use | Drug Resistance, Microbial | Pseudomonas Infections - epidemiology | Pseudomonas aeruginosa - pathogenicity | Respiratory Tract Infections - etiology | Respiratory Tract Infections - epidemiology | Nebulizers and Vaporizers
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 2015, Volume 15, Issue 2, pp. 225 - 234
Journal Article
BMC infectious diseases, ISSN 1471-2334, 07/2017, Volume 17, Issue 1, pp. 500 - 10
Background: Although the proportion of Pseudomonas aeruginosa infections has reduced after the introduction of antibiotics with anti-pseudomonal effects, P.... 
Pseudomonas aeruginosa | Child | Multidrug resistance | Antibiotic resistance | Neutropenia | INFECTIOUS DISEASES | RISK-FACTORS | MONOTHERAPY | METAANALYSIS | ANTIMICROBIAL THERAPY | COMBINATION THERAPY | CANCER | SURVEILLANCE | INFECTION | HEMATOLOGIC MALIGNANCIES | FEVER | Pseudomonas Infections - etiology | Humans | Child, Preschool | Bacteremia - mortality | Male | Pseudomonas Infections - mortality | Bacteremia - microbiology | Anti-Bacterial Agents - therapeutic use | Carbapenems - pharmacology | Neutropenia - microbiology | Penicillanic Acid - therapeutic use | Female | Retrospective Studies | Cephalosporins - pharmacology | Penicillanic Acid - analogs & derivatives | Thienamycins - therapeutic use | Pseudomonas Infections - drug therapy | Bacteremia - drug therapy | Fluoroquinolones - therapeutic use | Pseudomonas aeruginosa - drug effects | Amikacin - pharmacology | Neutropenia - drug therapy | Amikacin - therapeutic use | Carbapenems - therapeutic use | Fluoroquinolones - pharmacology | Adolescent | Drug Resistance, Multiple, Bacterial - drug effects | Fever - drug therapy | Aminoglycosides - therapeutic use | Piperacillin - therapeutic use | Infection | Medical research | Drug resistance in microorganisms | Leukemia | Mortality | Penicillin | Medicine, Experimental | Medical records | Beta lactamases | Health aspects | Bacteremia | Therapy | Pediatrics | Amikacin | Colistin | Disorders | Amides | Infections | Drug resistance | Risk factors | Demographics | E coli | Cephalosporins | Piperacillin | Impact resistance | Aminoglycoside antibiotics | Blood pressure | Meropenem | Teenagers | Children | Adolescents | Age | Pathogens | Automation | Acute lymphatic leukemia | Bacterial infections | Categories | Myeloid leukemia | Neutrophils | Lymphatic leukemia | Risk analysis | Patients | Studies | Antibiotics | Tazobactam | Immunocompromised hosts | Acute myeloid leukemia | Cancer
Journal Article
Journal Article